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As a part of a nationwide study in Spain, 15 clinical isolates of Acinetobacter genomic species 3 (AG3) were
analyzed. The main objective of the study was to characterize the ampC genes from these isolates and to
determine their involvement in -lactam resistance in AG3. The 15 AG3 isolates showed different profiles of
resistance to ampicillin (range of MICs, 12 to >256 g/ml). Nucleotide sequencing of the 15 ampC genes
yielded 12 new AmpC enzymes (ADC-12 to ADC-23). The 12 AG3 enzymes showed 93.7 to 96.1% amino acid
identity with respect to the AmpC enzyme from Acinetobacter baumannii (ADC-1 enzyme). Eight out of fifteen
ampC genes were expressed in Escherichia coli cells under the control of a common promoter, and with the
exception of one isolate (isolate 65, which showed lower -lactam MICs), significant differences in overall
-lactam MICs for E. coli cells expressing AG3 ampC genes were not revealed. No significant differences in
ampC gene expression in AG3 clinical isolates were revealed by reverse transcription-PCR analysis. A detailed
analysis of the 12 AmpC protein sequences revealed that amino acid replacements (in comparison with those
of ADC-1) occurred mainly in the same positions, although none were located in important functional domains
such as the- loop or conserved -lactamase motifs. Kinetic experiments performed with three representative
AmpC enzymes (ADC-14, -16, and -18) in some cases revealed dramatic changes in Km and kcat values for
-lactams. No ISAba1 was detected upstream of the ampC genes. Our results reveal 12 new ampC genes in AG3.
The enzymes showed a moderate degree of variability, and they are tentatively named ADC-12 to ADC-23.
Species belonging to the genus Acinetobacter are widely dis-
tributed in nature (2, 3) and are reported to be the cause of
ever-increasing numbers of nosocomial infections. Molecular
methods based on DNA-DNA hybridization or sequencing of
the 16S subunit of the ribosome have been described for up to
33 different groups (31). Groups 1, 2, 3, and 13 are phenotyp-
ically similar and traditionally known as the Acinetobacter cal-
coaceticus-Acinetobacter baumannii complex. Except for those
in group 1, these genomic species are important nosocomial
pathogens that frequently cause outbreaks of infection in in-
tensive care units and burn units (18, 20, 32). Although mech-
anisms of antibiotic resistance in A. baumannii have been de-
scribed (4, 6, 13, 14, 19, 23, 24, 31, 34, 35), there are few
descriptions of the mechanisms of resistance in Acinetobacter
genomic species 3 (AG3) (1, 10, 25, 29, 35). With regard to
-lactam resistance in AG3, two metalloenzymes, VIM-2 and
IMP-4, and a chromosomal cephalosporinase have been de-
scribed for this species (1, 10, 34, 35).
As a part of a nationwide, multicenter study in Spain, which
included analysis of 244 Acinetobacter sp. isolates (226 A. bau-
mannii, 15 AG3, and 3 unidentified isolates), we aimed to
determine the molecular basis of -lactam resistance and spe-
cifically ampicillin resistance in 15 AG3 clinical isolates. For
this purpose, the ampC genes from all isolates were sequenced
and further characterized to assess their activities and speci-
ficities toward -lactams. Overall, 12 new ampC genes were
discovered in AG3. Following a classification that is currently
under development, the genes were designated ADC-12 to
ADC-23.
MATERIALS AND METHODS
Bacterial strains. In November 2000, all A. baumannii isolates from clinical
samples were assembled from 28 hospitals in Spain. A total of 244 isolates of
Acinetobacter spp. were collected: 226 A. baumannii, 15 AG3, and 3 unidentified
Acinetobacter sp isolates. The 15 AG3 isolates used for further studies were
isolates 14, 20, 21, 52, 56, 60, 65, 67, 69, 90, 103, 109, 128, 195, and 243, which
were all isolated from different hospitals. Escherichia coli DH5 [F
80dlacZM15 (lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rk mk) phoA
supE44  thi-1 gyrA96 relA1] and E. coli BL21 [F ompT hsdSB(rB mB) gal
dcm] were used for determining antibiotic MICs and for analysis of expression
and purification of proteins, respectively.
Bacterial strains were frozen in Brucella glycerol broth (10%) (BBL Microbi-
ology Systems, Cockeysville, MD) and were maintained at 80°C until analysis.
Strains of E. coli were grown at 37°C in Luria-Bertani (LB) medium. When
necessary, LB medium was supplemented with ampicillin (20 g/ml) or kana-
mycin (50 g/ml) (Sigma-Genosys Ltd., United Kingdom).
Antimicrobial agents and determination of MICs. Antibiotic susceptibility
profiles were determined by Etest according to the manufacturer’s instructions
(AB Biodisk, Solna, Sweden). The following antibiotics were purchased from
Sigma-Aldrich (Madrid, Spain): ampicillin, piperacillin, cephalothin, cefoxitin,
cefuroxime, ceftazidime, and cefotaxime. Cefepime was obtained from Sigma-
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Genosys Ltd. (United Kingdom), imipenem was obtained from Merck Sharp and
Dohme (Madrid, Spain), and meropenem was obtained from AstraZeneca (Ma-
drid, Spain).
ARDRA. The species were identified by amplified ribosomal DNA restriction
analysis (ARDRA) (30). AG3 was also identified by sequencing of the 16S rRNA
gene with oligonucleotides P1 and P2 (Table 1).
REP-PCR. Repetitive extragenic palindromic sequence (REP)-based PCR
(REP-PCR) was used to evaluate the possible clonal relationship between the
different isolates of AG3 used in the study. The REP-PCR sequence allows
amplification of the localized regions between the REP zones. The primers used
are described in Table 1 (primers P3 and P4). The amplification reaction was
carried out as previously described (5). We consider that two isolates were
epidemiologically unrelated when two or more different bands were detected in
them (5, 33).
Cellular extract preparation and IEF. -Lactamases were obtained by soni-
cation of cultures of all isolates of AG3 grown overnight at 37°C in LB medium
and centrifugation at 14,000 rpm (MiniSpin microcentrifuge; Eppendorf, Ham-
burg, Germany) for 10 min (22). The pI values were determined as previously
reported with commercial isoelectric focusing (IEF) gels (pH 3.5 to 9.5; Phar-
macia LKB, Piscataway, NJ) by using a PhastSystem electrophoresis system
(Pharmacia). Sonicated extracts of microorganisms expressing -lactamases of
known pIs were used as controls.
Cloning experiments and recombinant plasmids. Total DNA was extracted
from 15 AG3 clinical isolates with the MasterPure DNA purification kit (Epi-
centre, Madison, WI) according to the manufacturer’s instructions. The ampC
genes from the 15 AG3 clinical isolates described above were cloned by PCR by
use of oligonucleotides P5 and P6 (Table 1) for isolates 21, 52, 60, 67, 90, 128,
and 243. For the remaining AG3 clinical isolates, oligonucleotides P5 and P7
were used. The Expand High Fidelity PCR system (Roche Diagnostics, India-
napolis, IN) was used for the amplification procedure under the following ex-
perimental conditions: denaturation at 94°C for 30 s, annealing at 55°C for 30 s,
and extension at 72°C for 1.5 min for a total of 28 cycles; an initial cycle of 2 min
at 94°C; and a final cycle of 10 min at 72°C. The amplicons were purified with a
High Pure PCR product purification kit (Roche Diagnostics, GmbH, Mannheim,
Germany). In 8 out of 15 isolates (isolates 14, 20, 56, 65, 69, 109, and 195), and
for expression and MIC studies, the amplified fragment was cloned into BamHI
and HindIII sites in pBGS18 (harboring a kanamycin resistance marker) under
the control of the strong promoter of the CTX-M-14 -lactamase gene (positions
1501 to 1740 [GenBank accession number AF252622]) (13). With the remaining
seven AG3 isolates, the amplified fragment was directly cloned into pBGS18 at
the same restriction sites. In both cases, ligation was carried out with a Rapid
DNA ligation kit (Roche Diagnostics, Indianapolis, IN). The DNA was electro-
porated in E. coli DH5 cells, and the clones were selected on LB plates with 20
g/ml of ampicillin and 50 g/ml of kanamycin. Plasmids from selected trans-
formants were purified and examined to check the accuracy of the cloning
procedure. Two clones from each gene transformation were selected, and nu-
cleotide sequencing was carried out. Sequencing of nucleotides was performed
by use of the Taq DyeDeoxiTerminator cycle sequencing kit before analysis using
an automatic DNA sequencer (377 Abi-Prism; Perkin-Elmer). Each gene was
sequenced on both strands. The ClustalW program (http://infobiogen.fr) was
used to align the multiple protein sequences (28).
Detection of ISAba1 in AG3 isolates. ISAba1-like sequences were previously
identified immediately upstream of the blaAmpC gene in ceftazidime-resistant A.
baumannii isolates, where the strong promoter of the ISAba1 insertion increased
the expression of the blaAmpC gene (16). To find out whether the ISAba1 element
was present in AG3, a PCR assay was performed with primer pairs for this
element and the ampC gene from AG3 (primer pair P8/P9 was used to detect
ISAba1, and primer pair P8/P10 was used to detect ISAba1 upstream of the
ampC gene).
-Lactamase purification and kinetic experiments. Three representative
AmpC enzymes from isolates 65, 103, and 195 were purified for kinetic experi-
ments. For this, the ampC genes were cloned into vector pGEX-6P-1, which
allows the production of a fusion protein from glutathione S-transferase (GST)
and the AmpC enzyme. The primer pairs used for PCR amplification and cloning
into pGEX-6P-1 were P11/P14 for isolate 65, P12/P14 for isolate 103, and
P13/P14 for isolate 195 (Table 1). -Lactamase was purified to homogeneity by
use of the GST gene fusion system (Amersham Pharmacia Biotech, Europe,
GmbH) according to the manufacturer’s instructions. The mature purified pro-
teins lacking the GST fusion protein appeared on sodium dodecyl sulfate-poly-
acrylamide gels as a band of 43 kDa (95% purity). Kinetic experiments were
performed at 25°C using a Nicolete Evolution 300 spectrophotometer (Thermo
Electron Corporation, Waltham, MA) with quartz cuvettes of optical path
lengths of 1 and 0.2 cm. The tests were each repeated three times with phos-
phate-buffered saline (PBS) with 20 mg/liter bovine serum albumin. The kinetic
parameters kcat, Km, and kcat/Km were studied for the antibiotics ampicillin,
cephalothin, cefoxitin, cefuroxime, cefotaxime, ceftazidime, aztreonam, and imi-
penem. The Km values were calculated as Ki values in competitive assays with
Centa (Calbiochem, Merck, Darmstadt, Germany) as the substrate, as previously
described for putative poor substrates such as imipenem and meropenem. The
Vmax was calculated by considering an antibiotic concentration six times the Km
and by use of the Michaelis-Menten equation, as previously described (26).
Studies of the 50% inhibitory concentration (IC50) were conducted by incubating
the purified proteins (1 g/ml) for 10 min in the presence of inhibitors of class
A -lactamases (clavulanic acid and sulbactam).
Semiquantitative RT-PCR. To detect ampC gene expression, reverse trans-
criptase PCR (RT-PCR) was carried out with 15 AG3 clinical isolates as well as
with an Acinetobacter sp. isolate with a high level of ampC gene expression (as a
positive control). Total RNA was extracted from cultures grown overnight in LB
medium at 37°C with the Trizol Max bacterial RNA isolator kit (Invitrogen,
Carlsbad, CA), and the RNA was then treated with DNase (Sigma-Genosys Ltd.,
United Kingdom). The Qiagen OneStep RT-PCR kit was used for RT-PCR
analysis with a 200-ng sample of total RNA. The primers used for gene ampli-
TABLE 1. Oligonucleotides used in the study
Oligonucleotide Descriptionb Sequencea Reference(s) or source
P1 ARDRA F 5	-TGGCTCAGATTGAACGCTGGCGGC-3	 30
P2 ARDRA R 5	-TACCTTGTTACGACTTCACCCC-3	 30
P3 REP F 5	-TTTGCGCCGTCATCAGGC-3	 5, 33
P4 REP R 5	-ACGTCTTATCAGGCCTAC-3	 5, 33
P5 ampC F 5	-aaggatccATGCGATTTAAAAAAATTTC-3	 6
P6 ampC R 5	-aaaagcttAGGATATGTTTGGTTC-3	 6
P7 ampC R 5	-aaaagcttTTATTTCTTTATTGCATTC-3	 6
P8 ISAba1 F 5	-aaaggatccCTCTGTACACGACAAATTTCAC This study
P9 ISAba1 R 5	-aaagaattcCTCTGTACAGCATAAAAATAGAT This study
P10 amp Int R 5	-GCCGACTTGATAGAA-3	 This study
P11 ampC F pGEX (isolate 65) 5	-aaggatccGGCAATACACCAAAAGACCAAG-3	 This study
P12 ampC F pGEX (isolate103) 5	-aaggatccGGTAATACACCAAAAGAGCAA-3	 This study
P13 ampC F pGEX (isolate 195) 5	aaggatccGGCAATACACCAAAAGAACAAG-3	 This study
P14 ampC R pGEX 5	-aagaattcTCTTTTTTATGTTTAGCTACGG-3	 This study
P15 RT-PCR ampC F 5	-AAGTTTTAACTTTTTTCAAAG-3	 This study
P16 RT-PCR ampC R 5	-AATTACTGTCTAATAAAGTTT-3	 This study
P17 RT-PCR control gyrA F 5	-AATCTGCCCGTGTCGTT-3	 GenBank accession no. AY204699
P18 RT-PCR control gyrA R 5	-GCCATACCTACGGCGA-3	 GenBank accession no. AY204699
a Lowercase letters represent restriction sites and tail nucleotides.
b F, forward oligonucleotide; R, reverse oligonucleotide.
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fication were designed to hybridize in highly conserved fragments in all se-
quences of ampC genes (P15 and P16 in Table 1), which amplified an internal
product of 470 bp. As an internal control for the RT-PCR, the gyrA gene from
AG3 was used as a template with oligonucleotides P17 and P18 (Table 1), which
amplified the 344 bp of this gene. The conditions of the RT-PCR were as follows:
an initial cycle of reverse transcription at 50°C for 30 min, followed by amplifi-
cation of the DNA with a initial cycle of 15 min at 95°C, 23 cycles at 95°C for 1
min, 50°C for 1 min, and 72°C for 1 min and a final cycle of 10 min at 72°C.
Aliquots were removed during the amplification process at cycles 14, 18, and 22
(exponential phase of amplification). The bands were revealed in agarose gels, as
described above. The intensity of ampC gene bands was compared with that of
gyrA gene bands.
Western blot analysis. Western blot analysis was used to detect and assess
AmpC expression in the AG3 isolates with polyclonal antibodies raised against
ADC-7 (19). Bacterial extracts were obtained as described above for pI analysis
and were loaded onto sodium dodecyl sulfate-polyacrylamide gels (12%) in a
minigel apparatus (Bio-Rad, Hercules, CA). The proteins were transferred onto
Immobilon-P membranes (Millipore, Billerica, MA). The membranes were
blocked with 5% (wt/vol) blocking agent (skim milk) in PBS-Tween. After the
membranes were washed with PBS-Tween, they were incubated with a mixture of
the polyclonal rabbit anti-ADC-7 antiserum diluted 1:1,500. The membranes
were then washed and incubated with secondary conjugated rabbit antiserum
diluted 1:2,000 (ECL Western blotting reagent; Amersham Pharmacia Biotech,
United Kingdom). All incubations were done for 1 h at 25°C. The Western blot
was revealed by overlaying the membranes with luminol, a substrate of the
horseradish peroxidase enzyme, ligated to secondary antibody.
OMP purification. Purification and analysis of outer membrane proteins
(OMPs) were performed as previously described (13, 14) with bacterial AG3
isolates 20 and 103 (with clear ampicillin resistance) and isolates 21, 56, and 128
(ampicillin susceptible).
Determination of antibiotic MICs in the presence of cloxacillin and the efflux
pump inhibitors PAN and CCCP. To assess the putative role of an efflux pump
mechanism involved in -lactam resistance in AG3, antibiotic MICs in the
presence and absence of chemical efflux pump inhibitors were determined. Thus,
MICs were determined in the presence of 150 g/ml of cloxacillin as an inhibitor
of cephalosporinase activity (7) and of efflux pump inhibitors, such as carbonyl
cyanide m-chlorophenylhydrazone (CCCP; Sigma) at 25 M (5.1 g/ml) (15)
and Phe-Arg -naphthylamide dihydrochloride (PAN; Sigma) at 25 g/ml (8),
alone and with antibiotics.
Theoretical modeling of the three-dimensional structure of AmpC enzymes.
The theoretical three-dimensional structure of the ADC-12 enzyme was obtained
by theoretical homology modeling with different computer software packages:
BLAST (to align sequences), Deep View (to obtain the theoretical structure
from previously aligned genes), and UCSF Chimera (protein model edition). For
this, the ADC-12 sequence was compared with the previously published structure
of CMY-10 (Protein Data Bank accession number 1ZKJ) (21), which showed the
highest amino acid identity (45%). We used the Deep View program in combi-
nation with the Swiss-model server to generate a homology-based model of the
enzyme. As part of the default pipeline of the ProModII modeling program
(implemented in Swiss-model), a final step of structure “dumping” was per-
formed, resulting in an unrefined, fast energy minimization process, mainly with
the purpose of avoiding atomic clashes. No further minimization or molecular
dynamic equilibration was executed.
Nucleotide sequence accession numbers. The nucleotide sequences of the
ADC-type enzymes have been submitted to the GenBank database under
accession numbers AM283529 (ADC-12), AM283528 (ADC-13), AM283527
(ADC-14), AM283526 (ADC-15), AM283525 (ADC-16), AM283524 (ADC-
17), AM283523 (ADC-18), AM283522 (ADC-19), AM283521 (ADC-20),
AM283520 (ADC-21), AM283519 (ADC-22), and AM283518 (ADC-23).
RESULTS
IEF analysis and antimicrobial susceptibility pattern. IEF
was performed with sonicated extracts obtained from 15 AG3
isolates. A single pI of ca. 9 was detected in all strains, probably
corresponding to a chromosomal cephalosporinase. The anti-
biotic MICs determined by Etest for the 15 AG3 clinical iso-
lates are shown in Table 2. High MICs of cephalothin and
cefoxitin and a moderate degree of resistance to cefuroxime
and cefotaxime were observed with all AG3 clinical isolates.
Although most of the AG3 isolates were resistant to ampicillin
(as deduced from the Clinical and Laboratory Standards
Institute breakpoints for the Enterobacteriaceae determined
for ampicillin) (12), a wide range of MICs was obtained (12
to 
256 g/ml). With two of the isolates, isolates 20 and
103, high MICs of ampicillin were obtained (256 and 
256
g/ml, respectively). Interestingly, meropenem MICs were 6
and 3 g/ml for the same two isolates, respectively. The
MICs of meropenem for the remaining AG3 isolates were
within the range of 0.19 to 1 g/ml.
REP-PCR analysis. A different DNA band pattern was ob-
tained for each AG3 isolate by REP-PCR, and the isolates
were therefore assumed to be genetically unrelated (data not
shown).
Amino acid sequence diversity of AmpCs of AG3. The ampC
genes from AG3 clinical isolates were amplified and sequenced
as described in Materials and Methods. The 15 ampC genes
were composed of 1,152 nucleotides, which encode an open
reading frame of 384 amino acids. The ampC genes of isolates
52, 56, 60, and 195 were identical; thus, there was a total of 12
different AmpC-encoding gene sequences (Fig. 1). These se-
quences differ from those of the previously reported ADC-type
genes, and following the recently developed uniform numerical
system for this family of AmpC -lactamases, we tentatively
named them ADC-12 to ADC-23. To explain whether or not
differences in antibiotic MICs (mainly ampicillin) were due to
differences in the amino acid compositions of AmpC enzymes,
a detailed examination of the amino acid sequences of the
AmpC enzymes was carried out and compared with that of
AmpC from A. baumannii or ADC-1 (Fig. 1). Overall, the
genes showed 93.7 to 96.1% identity with ADC-1. Although a
moderate degree of genetic variability was observed, the pat-
TABLE 2. -Lactam susceptibility profile of AG3 isolates included in the study
-Lactam
MIC (g/ml) for AG3 isolate:
14 20 21 52 56 60 65 67 69 90 103 109 128 195 243
Ampicillin 32 256 24 48 24 32 32 48 32 12 
256 48 24 32 12
Piperacillin 16 24 24 12 12 24 16 16 16 12 24 16 12 24 32
Cephalothin 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256 
256
Cefoxitin 
256 
256 
256 
256 64 
256 128 
256 
256 128 192 
256 128 
256 48
Cefuroxime 32 48 48 32 16 64 24 48 32 16 48 32 32 64 32
Ceftazidime 3 4 6 3 1.5 3 4 3 4 6 4 3 3 4 4
Cefotaxime 24 16 24 12 4 24 12 16 16 12 16 16 12 24 16
Cefepime 3 4 12 2 2 4 3 4 3 16 3 2 2 6 3
Imipenem 0.25 1 0.38 0.25 0.19 0.25 0.19 0.19 0.25 0.38 0.75 0.19 0.12 0.19 0.19
Meropenem 0.50 6 1 0.50 0.38 0.75 0.50 0.50 0.25 0.75 3 0.38 0.19 1 0.25
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tern does not appear to follow a random profile, as some
positions are more likely to be replaced than others. Indeed,
some amino acid positions were replaced in at least four of the
ADC-type enzymes analyzed with more than one residue (Fig.
1) and are shown in Fig. 3. Graphical analysis revealed no
changes in the relationships with important domains or cata-
lytic regions of the AmpC enzyme. Analysis of amino acid
sequences of ADC-13 and ADC-16 (isolated from AG3 iso-
lates 20 and 103, for which the highest ampicillin MICs were
obtained) did not reveal any significant differences (in amino
acid composition or position) with respect to the remaining
ADC-type enzymes.
Cloning and expression of ampC genes in the E. coli host. To
confirm whether or not amino acid changes have any effect on
the phenotype of ampicillin or -lactam resistance, we cloned
and expressed several ampC genes in an E. coli host. For this,
ampC genes from clinical isolates 20 and 103 (ampicillin MICs
of 256 and 
256 g/ml) and those from clinical isolates 14, 56,
65, 69, 109, and 195 (ampicillin MIC ranges of 24 to 48 g/ml)
were cloned into pBGS18 under the control of a common
external CTX-M-14 gene promoter and were then transformed
into a common E. coli DH5 host, and the -lactam MICs
were determined (Table 3). The MICs of different -lactams,
including ampicillin and meropenem, were similar for all E.
coli transformants except the transformant that expresses the
-lactamase AmpC of AG3 isolate 65 (ADC-14), for which the
MICs were slightly lower.
Kinetic experiments. To confirm that differences in AmpC
amino acid sequence are related to differences in the catalytic
efficiency of AmpC enzymes toward -lactams, three represen-
tative AmpC enzymes were chosen for further biochemical
experiments. Those of AG3 isolates 65 (ADC-14), 103 (ADC-
16), and 195 (ADC-18) were purified to homogeneity, and the
kinetic parameters Km, kcat, and kcat/Km were determined (Ta-
ble 4). The three AmpC enzymes showed almost identical
catalytic efficiencies (kcat/Km) toward ampicillin and cephalo-
thin, although ADC-14 showed important differences regard-
ing the Km and kcat values, thus revealing differences in the
biochemical behavior. Indeed, the kcat for ampicillin of ADC-14
was between 13 and 8 times lower than the corresponding
values for ADC-18 and -16, respectively, and also 25 and 24
times lower for cephalothin, respectively. Moreover, ADC-14
showed a lower catalytic efficiency for cefoxitin than ADC-18
and ADC-16 (2.1 and 1.9 times, respectively), cefuroxime (3.4
and 4.4 times, respectively), and cefotaxime (6.4 and 4.4 times,
respectively), which are consistent with MICs obtained with E.
coli harboring ampC genes (Table 3). With regard to imi-
penem, the three enzymes had similar Km values, although the
kcat/Km values for ADC-18 were almost seven times higher. No
hydrolysis was detected with aztreonam.
Regarding the inhibition studies, IC50s showed a typical class
C profile, with high clavulanic acid IC50s. However, there was
a moderate degree of sulbactam inhibition, and the IC50s for
clavulanic acid and sulbactam with ADC-14 were lower, which
indicates that differences in amino acid sequence (primary
structure of the enzyme) are related to differences in the cat-
alytic properties of the ADC-type enzymes.
FIG. 1. Amino acid sequence alignment among the 12 AmpC -lactamases from AG3 (ADC-12 to -23) with respect to that of A. baumannii
(ADC-1). Amino acid differences are indicated. The typical -lactamase domains (SVSK, YSN, and KTG) and the -loop are double underlined.
The amino acid replacements present in at least four or more proteins (relative to that of ADC-1) with more than one residue are underlined. The
vertical arrow indicates the position of the 1 amino acid (after cleavage of signal peptide). ADC-1, AmpC from A. baumannii (see reference 6).
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Expression of the ampC gene in AG3. The next step was to
assess whether or not differences in -lactam MICs in AG3
clinical isolates may be due to differences in ampC gene ex-
pression. For this, Western blot analysis and RT-PCR were
carried out.
Western blot analysis of the sonicated AG3 extracts with
polyclonal rabbit antiserum against ADC-7 enzyme revealed
a protein band in each isolate, which corresponded to the
expected molecular mass (43 kDa) of the Acinetobacter sp.
AmpC and which migrated at the same level of ADC-7 (Fig.
2). Furthermore, the presence of the previously sequenced
ISAba1 (involved in high-level blaAmpC expression in A.
baumannii) (16) in the genome of the 15 AG3 isolates under
study was discounted by the results of a series of PCR-based
experiments (data not shown).
A band was observed at 470 bp by RT-PCR, which corre-
sponded to the ampC gene in all 15 strains. A band of 344 bp
of the gyrA gene (as an internal control) was observed in all
AG3 isolates. The ratios of ampC/gyrA among AG3 isolates 20,
21, 28, 65, 103 and 243 and one Acinetobacter sp. isolate over-
expressing the AmpC enzyme (isolate 92) were as follows: 1.9,
1.8, 1.7, 1.7, 1.6, 1.7, and 4.2, respectively. Therefore, no dif-
ferences in the amounts of mRNA in the ampC genes of AG3
clinical isolates 20 and 103 or the remaining AG3 clinical
isolates (with lower ampicillin MICs) were observed by semi-
quantitative RT-PCR (with the exception of positive control
isolate 92). Overall, AG3 clinical strains 20 and 103 (with high
ampicillin MICs) did not show higher ampC gene expression
than the remaining AG3 isolates.
OMP analysis. To assess whether or not differences in OMP
expression were associated with differences in susceptibility to
-lactams, OMP profiles were obtained from isolates 20 and
103 as well as from representative ampicillin-susceptible iso-
lates 21, 56, and 128. No differences in OMPs at molecular
masses of 22, 29, 33 to 36, 40, and 45 kDa were visualized
among the bacterial isolates (data not shown), thereby ruling
out the involvement of OMPs in ampicillin or -lactam resis-
tance in AG3 isolates.
Effect of cloxacillin and efflux pumps inhibitors on MICs. As
no differences in either OMP or AmpC expression among AG3
isolates or catalytic efficiency against ampicillin were observed
among AmpCs, we proposed that other mechanisms, such as
an efflux pump, may also be operating in some AG3 clinical
isolates and that this may account for differences in -lactam
MICs. The MICs of ampicillin, cephalothin, and meropenem
were therefore determined in the presence of cloxacillin,
CCCP, and PAN (Table 5). The antibiotic MICs for all AG3
clinical isolates were moderately lower in the presence of clox-
acillin, although the effect was most apparent with ampicillin
(between two and eight times lower). In the presence of the
efflux pump inhibitors PAN or CCCP, the antibiotic MICs
were slightly lower with some isolates, although the effect was
TABLE 3. MICs of -lactam antibiotics tested with E. coli DH5 carrying the ampC genes under the control of a common promotera
-Lactam
MIC (g/ml) for:
E. coli DH5
E. coli carrying ampC from AG3 isolate:
14 20 56 65 69 103 109 195
Ampicillin 3 128 96 96 32 96 128 64 96
Piperacillin 0.38 4 4 3 4 3 4 4 4
Cephalothin 3 
256 
256 
256 192 
256 
256 
256 
256
Cefoxitin 2 32 32 16 3 16 32 24 24
Cefuroxime 1.5 64 96 48 4 32 64 32 48
Ceftazidime 0.19 0.38 0.75 0.25 0.25 0.19 0.50 0.19 0.50
Cefotaxime 0.064 0.75 0.125 0.38 025 0.38 0.75 0.38 0.75
Cefepime 0.016 0.023 0.19 0.023 0.032 0.023 0.032 0.023 0.032
Imipenem 0.125 0.125 0.023 0.19 0.19 0.19 0.125 0.12 0.25
Meropenem 0.008 0.023 0.023 0.023 0.023 0.023 0.023 0.032 0.032
a Identical MICs were obtained with three different transformants.
TABLE 4. Kinetic experiments performed with AmpC enzymes from the indicated AG3 isolatesa
Drug
AmpC from isolate (ADC type)b:
65 (ADC-14) 103 (ADC-16) 195 (ADC-18)
Mean Km
(M) (SD)
Mean kcat
(s1) (SD)
kcat/Km
(s1 mM1)
Mean Km
(M) (SD)
Mean kcat
(s1) (SD)
kcat/Km
(s1 mM1)
Mean Km
(M) (SD)
Mean kcat
(s1) (SD)
kcat/Km
(s1 mM1)
Ampicillin 0.12 (0.04) 0.30 (0.08) 2,447.15 1.03 (0.4) 2.6 (0.66) 2,518.91 1.5 (0.47) 4.05 (1.06) 2,700.94
Cephalothin 6.73 (2.3) 56.52 (22.38) 8,398.16 139.24 (16.72) 1,380.80 ( 490.13) 9,916.65 148.27 (13.23) 1,418.36 (318.51) 9,566.33
Cefoxitin 0.02 (0.01) 0.02 (0.004) 941.18 0.18 (0.04) 0.33 (0.02) 1,875.71 0.13 (0.03) 0.27 (0.004) 1,992.54
Cefuroxime 0.02 (0.01) 0.01 (0.002) 529.41 0.27 (0.03) 0.62 (0.20) 2,342.1 0.27 (0.04) 0.48 (0.17) 1,791.05
Cefotaxime 0.08 (0.02) 0.004 (0.002) 48.19 0.32 (0.12) 0.07 (0.01) 211.84 0.2 (0.01) 0.06 (0.004) 306.93
Ceftazidime 26.09 (4.49) 0.01 (0.001) 0.38 110.34 (6.44) 0.02 (0.003) 0.22 84.02 (21.12) 0.02 (0.006) 0.25
Aztreonam 6.01 (1.26) ND NC 3.85 (0.49) ND NC 4.54 (0.41) ND NC
Imipenem 2.29 (0.60) 0.003 (0.001) 1.31 2.56 (0.73) 0.004 (0.0005) 1.56 2.51 (0.86) 0.02 (0.003) 9.57
a The IC50 values of clavulanate were 235.52 M ( 01.71), 1,462.48 M (111.07), and 1,928.02 M (357.02) for isolates 65, 103, and 195, respectively; the IC50
values of sulbactam were 1.12 M (0.29), 7.75 M (1.20), and 11.65 M (2.03) for isolates 65, 103, and 195, respectively.
b ND, not done; NC, not calculated.
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most evident with AG3 isolate 103, for which the ampicillin
MICs were at least 10.6 and 8 times lower with PAN and
CCCP, respectively. The meropenem MICs were four and
three times lower with the latter isolate, respectively. Cloxacil-
lin and CCCP also exerted a synergistic effect on cephalothin
MICs (
256 g/ml without inhibitors compared with 12 to 96
g/ml when both are added), which suggests the presence of an
efflux operating at a constitutively low level in AG3. MICs
of cloxacillin, PAN, and CCCP alone for AG3 isolates were
higher than the concentration used in combination with anti-
biotics at 150 g/ml, 25 g/ml, and 25 M (5.1 g/ml), respec-
tively. Therefore, MICs were the final effect of the antibiotic-
inhibitor combination rather than of the inhibitor by itself
(Table 5).
Theoretical modeling of the ADC enzymes. The theoretical
overall folding three-dimensional structure of the ADC-12 en-
zyme is shown in Fig. 3. -Lactamase domains (blue circles,
with domain I in green) and the -loop (turquoise) are shown
in Fig. 3, as are the amino acid replacements (orange circles) in
the ADC-type enzymes (relative to ADC-1) (Fig. 1). Amino
acid replacements are randomly located along the protein se-
quence regardless of the phenotype of conferred ampicillin or
-lactam resistance, and none of them appear to affect the
-loop or any of -lactamase domains (Fig. 3).
DISCUSSION
During the course of a multicenter study carried out in 2000,
244 Acinetobacter sp. isolates were analyzed. Fifteen of the
isolates were identified as belonging to AG3 (6.1%); these
microorganisms may represent an emergent genomic species
of Acinetobacter (11, 29). Very few reports have been made
regarding the role of -lactamases in -lactam resistance
mechanisms in AG3 (1, 10, 35). In the present study, the
range of ampicillin MICs for AG3 isolates was 12 to 
256
g/ml, with two isolates, isolates 20 and 103, showing high
MICs (256 and 
256 g/ml, respectively).
A possible involvement of AmpC hyperexpression in clinical
isolates was ruled out by RT-PCR analysis. Moreover, deter-
mination of MICs in the presence of cloxacillin revealed a
slight decrease in -lactam MICs. Therefore, although consti-
tutively present, the role of AmpC in -lactam resistance in
AG3 appears to be moderate (which is consistent with the
absence of ISAba1 upstream of the ampC gene); thus, the
treatment of infections caused by AG3 isolates with -lactams
should be avoided, as it cannot be ruled out that in the near
future, an ISAba1-like element may be inserted in the up-
stream region of the ampC gene, thus hyperexpressing the
protein.
The sequencing of nucleotides and the deduced amino acid
sequence of the 13 ampC genes reported here showed some
degree of genetic variability. Although 4 out of 15 AG3 clinical
isolates harbored an identical ampC gene (for which any epi-
demiological relationship was clearly discounted), the AmpC
enzymes under study revealed a set of amino acid replace-
ments, which, for unknown reasons, are located in specific
positions in the amino acid sequence (Fig. 1). A steric view of
these mutations in the overall fold structure of the modeled
ADC-12 -lactamase (Fig. 3) revealed that these replacements
FIG. 2. Western blotting with anti-ADC-7 antibody and with protein extracts (10 g) obtained from the 15 different AG3 isolates indicated
above the gel. Purified ADC-7 enzyme (15 ng) (a gift from R. A. Bonomo) (C) and protein extracts of an Acinetobacter sp. isolate overexpressing
the AmpC enzyme (isolate 92) were included as positive controls.
TABLE 5. MICs for AG3 isolates in the presence of the indicated inhibitors
AG3
isolate
MIC (g/ml)a
MIC
of
CCCP
(M)b
Negative control in
the presence of:
Cloxacillin in the
presence of:
PAN in the presence
of:
CCCP in the
presence of:
Cloxacillin  PAN
in the presence of:
Cloxacillin 
CCCP in the
presence of: Cloxacillinb PANb
AMP CE MEM AMP CE MEM AMP CE MEM AMP CE MEM AMP CE MEM AMP CE MEM
14 32 
256 0.5 4 128 0.25 32 
256 0.25 24 
256 0.25 16 128 0.38 6 24 0.25 2,048 
400 400
20 256 
256 6 128 
256 3 96 
256 3 192 
256 4 128 
256 3 64 24 1.5 1,024 
400 400
21 24 
256 1 8 
256 0.5 12 
256 0.47 12 
256 0.5 4 192 0.64 6 48 0.25 512 
400 
400
52 48 
256 0.5 8 
256 0.19 48 
256 0.38 16 
256 0.38 8 
256 0.5 6 12 0.094 1,024 400 
400
56 24 192 0.38 6 
256 0.38 16 
256 0.094 24 96 0.25 8 
256 0.38 6 16 0.125 512 
400 
400
60 32 
256 0.75 16 
256 0.75 32 
256 0.19 32 
256 0.5 12 
256 0.75 8 28 0.25 1,024 400 
400
65 32 
256 0.5 16 128 0.19 32 
256 0.25 16 128 0.25 16 128 0.38 12 24 0.19 1,024 
400 
400
67 48 
256 0.5 8 128 0.25 48 
256 0.25 32 192 0.25 8 128 0.25 8 24 0.19 1,875 400 
400
69 32 
256 0.25 8 
256 0.19 32 
256 0.25 24 
256 0.25 8 
256 0.38 6 24 0.19 
2,048 400 
400
90 12 
256 0.75 6 192 1 12 
256 0.38 8 
256 1.5 6 64 0.25 2 24 0.38 512 
400 
400
103 
256 
256 3 64 192 1.5 48 
256 0.75 64 
256 1 12 192 0.75 16 24 1 1,024 400 
400
109 48 
256 0.38 6 128 0.25 48 
256 0.25 32 
256 0.25 8 128 0.38 4 24 0.19 2,048 400 
400
128 24 
256 0.19 8 48 0.25 24 
256 0.125 24 
256 0.19 8 48 0.19 4 32 0.094 2,048 400 
400
195 32 
256 1 16 
256 1 48 
256 1 32 
256 0.5 16 
256 1 16 96 0.38 1,024 400 
400
243 12 
256 0.25 4 192 0.125 12 
256 0.19 8 
256 0.25 4 192 0.19 2 12 0.094 2,048 
400 400
a AMP, ampicillin; CE, cephalothin; MEM, meropenem; negative control, no inhibitor added.
b Only inhibitor added.
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are located far from the active site of the enzyme. However,
although there were no significant differences in MICs among
different ADC-type enzymes, the biochemical analysis of three
representative AmpC enzymes (ADC-14, -16, and -18) (one
isolated from a highly ampicillin-resistant AG3 isolate and the
other two isolated from ampicillin-susceptible AG3 strains) did
reveal significant differences in some of the measured kinetic
parameters (Table 4). This supports the idea that whereas
some amino acid changes may be neutral, others are associated
with dramatic changes in the catalytic efficiency or biochemical
parameters of the AmpC enzymes (see Km and/or kcat values
for ADC-14 and cephalosporins in comparison with ADC-16
and -18).
Other mechanisms such as a loss of porins, efflux pumps, and
penicillin binding protein alterations may be involved in -lac-
tam resistance in Acinetobacter spp. (13, 14, 24). To study the
involvement of non-AmpC-related mechanisms in some -lac-
tam MICs, we studied OMP and efflux pump expression.
Efflux pumps have been described for A. baumannii and
AG3 (9, 17, 27) and have been detected in the recently re-
vealed genome of Acinetobacter baylyi (www.genoscope.fr).
Thus, experiments were carried out with the chemical inhibi-
tors PAN and CCCP. The ampicillin MICs decreased (by at
least 10 times) only for AG3 isolate 103 in the presence of
either PAN or CCCP, thus revealing that efflux pumps may
operate by pumping out -lactams in some AG3 strains.
In summary, we report here the identification and analysis of
12 new ampC genes from AG3. We also report further infor-
mation regarding -lactam resistance in AG3. A uniform nu-
merical system for the classification of cephalosporinase from
Acinetobacter spp. is currently under development, and in ac-
cordance with this classification, we tentatively named our 12
new AmpC enzymes ADC-12 to ADC-23.
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